首页> 外文期刊>Transplantation Proceedings >Closure and summary of Ninth International Small Bowel Transplantation Symposium.
【24h】

Closure and summary of Ninth International Small Bowel Transplantation Symposium.

机译:第九届国际小肠移植研讨会的闭幕和摘要。

获取原文
获取原文并翻译 | 示例
       

摘要

The highlights of The Ninth International Small Bowel Transplantation Symposium included the latest results from the Intestinal Transplant Registry (ITR), which demonstrated that the number of transplants performed annually continued to rise to 180 per year, most of which were performed in the United States, where the greatest number of home parenteral nutrition (PN) patients live (a prevalence of around 40 per million or 10,000 individuals). The three largest programs in the United States all use anti-CD25 monoclonal antibodies, but three different forms of lymphocyte depletion are employed in induction protocols: (1) humanized monoclonal anti-thymocyte globulin; (2) pretreatment of the recipient with Campath; (3) pretreatment of the small bowel allograft with anti-lymphocyte globulin. The main gain in these new approaches has been in the reduction in tacrolimus and steroid exposure. Indeed, the Pittsburgh team reduced tacrolimus to alternate-day dosing and stopped steroids altogether at 6 months in some patients, recording 100% survival in the past 2 years. The ITR demonstration of a difference in survival between adult patients who are hospitalized (40% to 60%) versus those who are still at home (80% to 100% survival) when called to transplant makes it almost unethical to delay evaluating patients for small bowel transplantation once they start experiencing complications on home PN. The input of gastroenterologists is also crucial in making recommendations about isolated liver transplantation for individuals with a potential to come off PN. Several important papers with useful prognostic clinical data with respect to selecting patients for isolated liver transplant were presented. It is evident from demographic surveys that only 2% to 5% adult patients and 5% to 15% children in large, well-resourced PN programs will be unlucky enough to develop life-threatening complications, but they must have rapid access to small bowel transplantation in this event. It is therefore important that the collaboration between gastroenterologists and the intestinal transplant teams continues. These excellent results for small bowel transplantation mean that the time is right for a large cost-effectiveness study comparing small bowel transplantation with PN.
机译:第九届国际小肠移植专题讨论会的要点包括肠移植注册表(ITR)的最新结果,该结果表明每年进行的移植数量继续增加到每年180次,其中大部分是在美国进行的,最多的家庭肠胃外营养(PN)患者居住的地方(每百万或10,000个人中约40个患病率)。美国三个最大的计划都使用抗CD25单克隆抗体,但在诱导方案中采用了三种不同形式的淋巴细胞耗竭:(1)人源化单克隆抗胸腺细胞球蛋白; (2)使用Campath预处理接收者; (3)用抗淋巴细胞球蛋白预处理小肠同种异体移植物。这些新方法的主要好处是减少了他克莫司和类固醇的暴露。的确,匹兹堡研究小组将他克莫司减少为隔日给药,并在某些患者中于6个月完全停止使用类固醇,在过去2年中记录了100%的存活率。 ITR证明,在被移植时,住院的成年患者(40%至60%)与仍在家中的成年患者(存活率80%至100%)之间存在生存差异,这使得延迟评估小患者的行为几乎是不道德的一旦他们开始在家庭PN上遇到并发症,便进行肠移植。肠胃科医生的意见对于为有可能脱离PN的个体提供有关离体肝移植的建议也至关重要。提出了几篇重要的论文,这些论文具有关于选择离体肝移植患者的有用的预后临床数据。从人口统计调查中可以明显看出,在资源充足的大型PN项目中,只有2%至5%的成年患者和5%至15%的儿童会不幸地招致致命的并发症,但他们必须能够快速进入小肠在这种情况下进行移植。因此,重要的是要继续胃肠病学家和肠移植团队之间的合作。小肠移植的这些优异结果意味着将小肠移植与PN进行比较的大型成本效益研究的时机已经成熟。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号